409 related articles for article (PubMed ID: 26182875)
21. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Hasegawa M; Miyajima A; Kosaka T; Yasumizu Y; Tanaka N; Maeda T; Shirotake S; Ide H; Kikuchi E; Oya M
Int J Cancer; 2012 Jan; 130(2):431-42. PubMed ID: 21351099
[TBL] [Abstract][Full Text] [Related]
22. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.
Ahmad A; Kong D; Sarkar SH; Wang Z; Banerjee S; Sarkar FH
J Cell Biochem; 2009 Jun; 107(3):516-27. PubMed ID: 19330806
[TBL] [Abstract][Full Text] [Related]
24. RKIp inhibits the migration and invasion of human prostate cancer PC-3M cells through regulation of extracellular matrix.
Xinzhou H; Ning Y; Ou W; Xiaodan L; Fumin Y; Huitu L; Wei Z
Mol Biol (Mosk); 2011; 45(6):1004-11. PubMed ID: 22295570
[TBL] [Abstract][Full Text] [Related]
25. Y27632 attenuates the aristolochic acid-promoted invasion and migration of human urothelial cancer TSGH cells in vitro and inhibits the growth of xenografts in vivo.
Huang HP; Wang CJ; Tsai JP; Wu SW; Hung TW; Lian JD; Chang HR
Nephrol Dial Transplant; 2012 Feb; 27(2):565-75. PubMed ID: 21799205
[TBL] [Abstract][Full Text] [Related]
26. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
27. PEITC inhibits human brain glioblastoma GBM 8401 cell migration and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of MMP-2, -7 and -9 gene expression.
Chou YC; Chang MY; Wang MJ; Yu FS; Liu HC; Harnod T; Hung CH; Lee HT; Chung JG
Oncol Rep; 2015 Nov; 34(5):2489-96. PubMed ID: 26352173
[TBL] [Abstract][Full Text] [Related]
28. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2011 Dec; 26(6):1407-13. PubMed ID: 21874261
[TBL] [Abstract][Full Text] [Related]
30. Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells.
Chen HJ; Lin CM; Lee CY; Shih NC; Peng SF; Tsuzuki M; Amagaya S; Huang WW; Yang JS
Oncol Rep; 2013 Aug; 30(2):925-32. PubMed ID: 23708932
[TBL] [Abstract][Full Text] [Related]
31. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
[TBL] [Abstract][Full Text] [Related]
33. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
34. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
35. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
[TBL] [Abstract][Full Text] [Related]
36. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Senthilkumar K; Arunkumar R; Elumalai P; Sharmila G; Gunadharini DN; Banudevi S; Krishnamoorthy G; Benson CS; Arunakaran J
Cell Biochem Funct; 2011 Mar; 29(2):87-95. PubMed ID: 21308698
[TBL] [Abstract][Full Text] [Related]
37. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
38. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Kong D; Li Y; Wang Z; Banerjee S; Sarkar FH
Cancer Res; 2007 Apr; 67(7):3310-9. PubMed ID: 17409440
[TBL] [Abstract][Full Text] [Related]
40. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]